» Educational Qualifications

» Publications

SCI-SSCI or SCI Expanded Articles

  • .O. KÖSTEK, Y. BOZKAYA, B. M. HACIOGLU, N. Ö. YILDIRIM, E. YILMAZ, C. N. DEMIRCAN, B. ERDOGAN, S. UZUNOGLU, I. ÇIÇIN, N. ZENGIN, Is the Charlson Comorbidity Index a Prognostic Indicator for Toxicity and Mortality in Elderly Patients with Locally Advanced Rectal Cancer?, Archives of Iranian Medicine, vol. 22, no. 1, pp. 236-241, 5, 2019.
  • .O. KÖSTEK, B. M. HACIOGLU, A. SAKIN, T. DEMIR, M. SARI, Ö. ÖZKUL, M. ARAZ, F. A. DOGAN, C. N. DEMIRCAN, S. UZUNOGLU, I. ÇIÇIN, B. ERDOGAN, Regorafenib or rechallenge chemotherapy: Which is more effective in the third-line treatment of metastatic colorectal cancer?, CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 83, no. 1, pp. 115-122, 1, 2019.
  • .S. DEGIRMENCIOGLU, Ö. TANRIVERDI, S. MENEKSE, M. DOGAN, B. M. HACIOGLU, E. OKTAY, E. DILEK, E. ARPACI, B. U. OYAN, S. TURHAL, M. YILMAZ, K. PILANCI, A. SAKIN, M. ARAZ, S. ÇOKMERT, Ö. ÖZDEMIR, E. SEN, E. NAYIR, A retrospective analysis on first-line bevacizumab, cetuximab,and panitumumab-containing regimens in patients with RASwildmetastatic colorectal cancer: A Collaborative Study byTurkish Oncology Group (TOG), Journal of BUON, vol. 24, no. 1, pp. 242-248, 1, 2019.
  • .D. TURAL, M. KARACA, A. ZIRTILOGLU, B. M. HACIOGLU, N. A. M. SENDUR, A. ÖZET, Receptor discordances in locally advanced breast cancer afterneoadjuvant chemotherapy and their effects on survival, Journal of BUON, vol. 24, no. 1, pp. 20-25, 1, 2019.
  • .A. GÖKYER, A. KÜÇÜKARDA, O. KÖSTEK, B. M. HACIOGLU, S. B. SUNAL, C. N. DEMIRCAN, S. UZUNOGLU, S. SOLAK, K. ISSEVER, I. ÇIÇIN, B. ERDOGAN, Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib, Clinical and Translational Oncology, 3, 2019.
  • .O. KÖSTEK, E. YiLMAZ, B. M. HACIOGLU, C. N. DEMIRCAN, A. GÖKYER, S. UZUNOGLU, N. TUNÇBILEK, I. ÇIÇIN, B. ERDOGAN, Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer, Cancer Chemotherapy and Pharmacology, vol. 83, no. 4, pp. 735-742, 4, 2019.

International Articles

  • .O. KÖSTEK, B. M. HACIOGLU, Effect of Somatostatin Analogs on Prostate Volume, Medeniyet Medical Journal, vol. 34, no. 1, pp. 76-81, 6, 2019.

National Articles

  • .S. SAHIN, B. M. HACIOGLU, Treatment Outcomes of Metastatic Colorectal Cancer Patients Treated with Regorafenib as Third-Line Setting-A Multicenter Study, Istanbul Medical Journal, vol. 20, no. 2, pp. 82-87, 4, 2019.

Other

  • .B. M. HACIOGLU, I. ÇIÇIN, Immünoterapilerde Yan Etki Yönetimi, Ulusal, Bölüm: Immünoterapilerin Nadir Toksisiteleri ve Yönetimi, Basim Türü: Basili, pp. 120-144, TÜRKIYE-Ankara, ISBN978-605-7650-02-3, Türkiye Klinikleri, 20191. Basim.
  • .B. M. HACIOGLU, B. ERDOGAN, I. ÇIÇIN, GEBELIKTE KANSER TEDAVISI, Ulusal, Bölüm: GEBELIK VE SARKOMLAR, Basim Türü: Basili, pp. 195-205, TÜRKIYE-ANKARA, ISBN978-975-277-675-3, GÜNES TIP KITABEVI, 20191. Basim.